Prothena Corp. (NASDAQ:PRTA) saw unusually-high trading volume on Friday . Approximately 508,162 shares were traded during mid-day trading, a decline of 20% from the previous session’s volume of 632,120 shares.The stock last traded at $48.11 and had previously closed at $45.64.

PRTA has been the subject of a number of analyst reports. Credit Suisse Group AG reissued a “buy” rating on shares of Prothena Corp. in a report on Tuesday, July 12th. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corp. in a report on Wednesday, June 22nd. Zacks Investment Research raised Prothena Corp. from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. Barclays PLC initiated coverage on Prothena Corp. in a report on Friday, May 13th. They issued an “overweight” rating and a $60.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and issued a $77.00 price target on shares of Prothena Corp. in a report on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $74.60.

The company has a 50-day moving average price of $43.35 and a 200-day moving average price of $42.16. The stock’s market cap is $1.67 billion.

Prothena Corp. (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.04. On average, analysts expect that Prothena Corp. will post ($3.72) earnings per share for the current year.

In other Prothena Corp. news, Director Dennis J. Selkoe sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the transaction, the director now directly owns 3,025 shares in the company, valued at $136,125. The transaction was disclosed in a filing with the SEC, which is available through this link.

A number of institutional investors recently bought and sold shares of PRTA. State Board of Administration of Florida Retirement System raised its position in Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock valued at $1,182,000 after buying an additional 803 shares during the period. Nationwide Fund Advisors raised its position in Prothena Corp. by 77.8% in the fourth quarter. Nationwide Fund Advisors now owns 35,835 shares of the company’s stock valued at $2,441,000 after buying an additional 15,683 shares during the period. California State Teachers Retirement System raised its position in Prothena Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 57,940 shares of the company’s stock valued at $3,946,000 after buying an additional 900 shares during the period. American Century Companies Inc. raised its position in Prothena Corp. by 36.8% in the fourth quarter. American Century Companies Inc. now owns 41,054 shares of the company’s stock valued at $2,796,000 after buying an additional 11,043 shares during the period. Finally, Rhumbline Advisers raised its position in Prothena Corp. by 7.5% in the fourth quarter. Rhumbline Advisers now owns 30,805 shares of the company’s stock valued at $2,098,000 after buying an additional 2,140 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.